We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc | NASDAQ:ALNY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.92 | -0.60% | 151.37 | 150.88 | 152.99 | 153.00 | 150.37 | 153.00 | 329,128 | 21:00:10 |
From May 2023 to May 2024
By Sabela Ojea
Alnylam Pharmaceuticals said that it received a positive review from the U.S. Food and Drug Administration regarding its supplemental new drug application to treat a heart disease through its Onpattro drug.
The biopharmaceutical company said 9 out of 12 members of the cardiovascular and renal drugs Advisory committee voted that the benefits of its medication outweigh its risks for the treatment of cardiomyopathy of ATTR amyloidosis.
Transthyretin amyloid cardiomyopathy is a rare but severe cause of cardiomyopathy that takes place as a result of an accumulation of the transthyretin protein.
"We look forward to continuing to work with the FDA as they complete their review of our sNDA," said Pushkal Garg, Alnylam's chief medical officer.
Earlier on Wednesday, Alnylam Pharmaceuticals shares were halted from trading while the regulatory advisory committee met to review its sNDA.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 13, 2023 17:33 ET (21:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Alnylam Pharmaceuticals Chart |
1 Month Alnylam Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
